- Home
- RAPP vs NEO Comparison
RAPP vs NEO Comparison
Compare RAPP & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAPP | NEO |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2024 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RAPP | NEO |
|---|---|---|
| Price | $29.66 | $11.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $46.60 | $12.56 |
| AVG Volume (30 Days) | 388.2K | ★ 1.9M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | N/A | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $6.43 | $4.72 |
| 52 Week High | $42.27 | $19.12 |
Technical Indicators
Market Signals| Indicator | RAPP | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 62.11 |
| Support Level | $26.92 | $11.66 |
| Resistance Level | $30.44 | $12.26 |
| Average True Range (ATR) | 1.80 | 0.49 |
| MACD | 0.20 | 0.04 |
| Stochastic Oscillator | 90.28 | 72.85 |
Price Performance
Historical ComparisonAbout RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.